FDA Status
Not FDA-Approved
Claimed Benefits
- Selective GH secretion without cortisol increase
- GI prokinetic activity
- Protection against glucocorticoid-induced muscle loss
Clinical Evidence
3
Human Trials
Phase II
Highest Phase
Phase II RCTs found ipamorelin safe and well-tolerated, but primary GI motility endpoints did not reach significance vs. placebo.
Read Full Deep Dive
Mechanism, dosing, vendor pricing, and full research citations